Intech Investment Management Reduces $15M in Cardinal Health, Inc. ($CAH)
Intech Investment Management slashed its holdings in Cardinal Health by nearly 30% as of its recent SEC filing.
Key Points
- Intech Investment Management reduced its stake in Cardinal Health by 29.9%, selling 62,358 shares to hold 146,183 shares valued at $32.7 million.
- Cardinal Health trades on the NYSE at around $223.85, with a market cap of $52.4 billion and a forward P/E of 18.7.
- Analysts maintain a strong buy consensus, with a target price averaging $245.27 across 15 opinions.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Intech Investment Management has made a significant reduction in its position in Cardinal Health, Inc. (NYSE:CAH). According to the latest Form 13F filing with the SEC, Intech cut its holdings by 29.9%, selling 62,358 shares to bring its total down to 146,183 shares. The value of this position is approximately $32.7 million as of the reporting period.
What Changed in Intech Investment Management's Cardinal Health Position
Intech Investment Management trimmed its stake in Cardinal Health from 208,541 shares to 146,183 shares, a decrease of 62,358 shares or 29.9%. This reduction reflects a repositioning in their investment portfolio, with the remaining shares valued at about $32.7 million.
Other Institutional Activity in Cardinal Health
Several other institutional investors also adjusted their positions in Cardinal Health. BlackRock, Inc. reduced its holdings by 146,765 shares, ending with 28,494,855 shares valued at approximately $6.02 billion. Vanguard Capital Management LLC significantly increased its stake, adding 15,288,709 shares to hold 15,288,709 shares worth about $3.23 billion. Similarly, Vanguard Portfolio Management LLC added 13,732,309 shares, bringing its total to 13,732,309 shares valued at $2.90 billion. State Street Corp decreased its position by 434,712 shares, holding 12,074,518 shares valued at $2.55 billion. Geode Capital Management, LLC increased its holdings by 51,519 shares, totaling 6,580,532 shares worth approximately $1.39 billion.
Cardinal Health, Inc. Stock Up 1.3%
Shares of Cardinal Health are trading around $223.85 on the NYSE. The company has a market capitalization of $52.4 billion, with a P/E ratio of 34.1 and a forward P/E of 18.7, indicating expectations of future earnings growth. The stock's 52-week range is between $137.75 and $233.6, with a 50-day moving average of $202.78 and a 200-day moving average of $195.75. Cardinal Health's beta is 0.526, suggesting lower volatility compared to the market.
$CAH stock price
Daily closing prices, year to date. Not investment advice.
Recent Earnings
Cardinal Health reported a revenue of $250.7 billion with a growth rate of 11%. The net margin stands at 0.62%, and the return on equity is not specified. The company's next earnings report is expected on April 30, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
2 target raises vs 2 cuts.
-
EPS & revenue
EPS beat estimates by 12.6%. Revenue missed estimates by 2.2%.
-
Profit surprise
EBITDA missed by 27 percent. Operating income missed by 46 percent.
-
Pre-earnings setup
Bar was high, analysts already very bullish.
-
Analyst signal
2 target raises, 2 target cuts.
-
Earnings quality
Positive free cash flow.
Earnings Call Summary
Cardinal Health reported first quarter revenue of $60.9 billion, up 22 percent year over year, with earnings per share of $3.17 beating consensus of $2.80. The company saw broad strength across all five business segments, particularly in pharmaceutical specialty solutions where profit grew 26 percent and specialty drug sales benefited from GLP-1 demand growth. The strong quarter reflected execution on strategy, successful integration of acquisitions, and robust underlying pharmaceutical utilization trends across the market.
Guidance Cardinal Health raised its full year earnings guidance to between $9.65 and $9.85 per share, up 35 cents from prior guidance. The company expects Pharma profit to grow 16 to 19 percent for the year, driven by strong drug demand and the Solaris Health acquisition closing soon. Free cash flow is now guided to $3 billion to $3.5 billion for the full year, up from prior range.
Clearly negative report. The company missed important expectations and likely triggers downward revisions.
Dividend
Cardinal Health offers an annual dividend rate of $2.05, yielding 0.91% with a payout ratio of 31.2%. This provides a steady income stream for investors.
Insider Buying and Selling at Cardinal Health, Inc.
Recent insider activity at Cardinal Health includes Patricia Hemingway Hall purchasing 381 shares at $207.83 on April 15, 2026. Meanwhile, Michelle Greene, the Chief Information Officer, sold 2,746 shares at an average price of $228.47 on February 27, 2026. Aaron Alt, the Chief Financial Officer, sold multiple batches of shares totaling over 6,000 shares in February 2026 at prices ranging from $220.79 to $225.5.
Analysts Set New Price Targets
Analysts have maintained positive ratings on Cardinal Health. On May 4, 2026, JP Morgan maintained a hold rating with a $215 target price. Citigroup, TD Cowen, and Wells Fargo all maintained buy ratings with target prices of $245, $255, and $245, respectively, on May 1, 2026. The consensus among analysts is a strong buy, with an average target price of $245.27 based on 15 analyst opinions.
About Cardinal Health
Cardinal Health, Inc. is a healthcare services and products company based in Dublin, Ohio. It operates in two main segments: Pharmaceutical and Specialty Solutions, and Global Medical Products and Distribution. The company provides a range of services to healthcare facilities, including hospitals, pharmacies, and clinical laboratories. Cardinal Health also manufactures and distributes medical and surgical products, offering solutions that span the healthcare supply chain. Led by CEO Jason M. Hollar, the company employs over 53,000 people.
Bottom Line
Intech Investment Management's decision to reduce its stake in Cardinal Health by nearly 30% is a notable adjustment in its investment strategy. Investors often track such moves to gauge institutional sentiment, though it's worth noting that 13F filings are backward-looking and may not reflect current holdings. Cardinal Health remains a strong player in the healthcare distribution sector, with analyst consensus suggesting optimism about its future performance.
Get Cardinal Health, Inc. alerts
New 13F filings, insider trades, and analyst moves on $CAH, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.